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Abstract
Objective: The objective was to determine the safety of ocrelizumab (OCR) in patients with rheumatoid arthritis (RA).
Methods: This was an analysis of the double-blind, placebo-controlled periods and long-term follow-up of 4 OCR phase III
trials in RA (SCRIPT, STAGE, FILM and FEATURE). Safety data per study and the results of a meta-analysis of serious infectious
events (SIEs) are presented.
Results: Overall, 868 patients received placebo, 1064 patients OCR 200 mg62 (or 400 mg61) (OCR200), and 827 patients
OCR 500 mg62 (OCR500) plus background methotrexate (MTX) at baseline and 24 weeks. During the double-blind,
placebo-controlled periods, the incidence of adverse events and serious adverse events was comparable between the OCR+
MTX and placebo +MTX groups. Infusion-related reactions were more common with OCR+MTX and decreased in frequency
with subsequent infusions. Serious infusion-related reactions were rare (0.1%). Serious infections occurred more frequently
with OCR500+MTX. In the meta-analysis, a statistically significant difference from placebo +MTX in incidence of SIEs per 100
patient-years of 2.4 (95% CI, 0.3–4.5) was observed with OCR500+MTX, but not with OCR200+MTX (0.6; 95% CI, 21.3 to 2.4).
Patients recruited in Asia exhibited a higher risk of serious infections (hazard ratio, 1.78; 95% CI, 1.03–3.06). The incidence of
human anti-human antibodies was ,5%. Long-term follow-up indicated no differences in malignancy rates between the
treatment groups. There was no apparent difference in time to B-cell repletion between the OCR dose groups.
Conclusions: In placebo-controlled clinical trials of RA, OCR500+MTX was associated with a higher risk of serious infections
compared with placebo +MTX. The safety profile of OCR 200+MTX was comparable with placebo+MTX.
Trial Registration: STAGE Clinical Trials.gov NCT00406419 SCRIPT Clinical Trials.gov NCT00476996 FILM Clinical
Trials.gov NCT00485589 FEATURE Clinical Trials.gov NCT00673920
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Introduction
Although the immunopathogenesis of rheumatoid arthritis (RA)
is not fully understood, accumulating evidence suggests that B cells
have multiple potential roles through both antibody-dependent
and antibody-independent pathways [1,2]. Rituximab is a
chimeric mouse-human monoclonal antibody that depletes
CD20+ B cells and has been shown to be an effective therapy in
patients with RA [3–7]. Pooled analysis of long-term safety data
from patients receiving rituximab within a global clinical trial
program indicated that rituximab is well tolerated over time and
during multiple courses of treatment [8,9]. However, as with all
chimeric antibodies, immunogenicity may be a potential concern.
A safety analysis showed that 11% of patients with RA developed a
titer positive for human anti-chimeric antibody (HACA) on at least
one occasion during treatment with rituximab [8]. The presence of
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HACAs was not associated with the development of infusion-
related reactions (IRRs) or loss of efficacy on retreatment. Thus,
the clinical impact of HACA directed at rituximab remains
unclear.
Ocrelizumab (rhuMAb 2H7, [OCR]) is a humanized anti-
CD20 monoclonal antibody. In vitro characterization of OCR
demonstrated enhanced antibody-dependent cell-mediated cyto-
toxicity and reduced complement-dependent cytotoxicity com-
pared with rituximab (unpublished data), although the clinical
implications of these differences remain unclear. The efficacy and
safety of OCR in RA has been evaluated in a robust phase III
clinical trial program in a broad spectrum of patients [10–13]. In
May 2010, OCR development in RA was terminated as a result of
the overall risk-benefit assessment from the 2 pivotal phase III
studies STAGE and SCRIPT. The efficacy and safety profiles of
the OCR 200 mg (OCR200) and OCR 500 mg (OCR500) dosing
regimens led the sponsors to conclude that OCR did not
demonstrate an additional benefit over existing therapies, includ-
ing rituximab for patients with RA, and that an application for
regulatory approval of OCR in RA was not warranted. This paper
presents the key safety outcomes of the 4 phase III OCR trials in
RA to provide an overview of the safety of OCR in patients with
RA and background methotrexate (MTX) treatment.
Patients and Methods
The CONSORT checklist is available as supporting informa-
tion; see Checklist S1.
Ethics Statement
These studies were conducted at 686 sites across more than 20
different countries in accordance with the ethical principles of the
Declaration of Helsinki. Ethical approval from the local institu-
tional review board at each study center was obtained before the
start of each study and all patients provided written informed
consent. All studies included were previously registered with
ClinicalTrials.gov (registration nos. NCT00406419,
NCT00476996, NCT00485589 and NCT00673920).
Patients
Patients included in the analyses were participants in 1 of 4
OCR phase III trials [10–13]. The analysis population represented
a broad spectrum of patients, ranging from patients with early RA
who were MTX-naive (FILM [12], registration
no. NCT00485589) to patients with advanced RA disease who
were refractory to disease-modifying antirheumatic drugs
(DMARDs) (FEATURE [13], registration no. NCT00673920
and STAGE [10], registration no. NCT00406419) and/or anti-
TNFs (SCRIPT [11], registration no. NCT00476996). The
overwhelming majority of patients received background MTX;
leflunomide could also be used instead of MTX in SCRIPT.
Study Designs
All 4 trials were phase III international, randomized, and
double-blind, placebo-controlled (DBPC); STAGE was conducted
at 209 centers in 24 countries, SCRIPT was conducted at 227
centers in 25 countries, FEATURE was conducted at 96 centers in
14 countries and FILM was conducted at 154 centers in 21
countries. The study designs and numbers of patients randomized
were reported previously [10–13] and are summarized in Table 1.
During the DBPC period of STAGE, SCRIPT and FILM,
patients received treatment on Days 1 and 15 followed by a
retreatment course at Weeks 24 and 26 (patients in FILM were
eligible for 2 additional retreatment courses at Weeks 52 and 54,
and Weeks 76 and 78). At the end of the DBPC period in
FEATURE (Week 24), all patients were re-randomized to receive
either OCR20062+MTX or OCR 400 mg (OCR400) +MTX for
a 24-week double-blind (but not placebo-controlled) treatment
period. After completion of the double-blind period (48 weeks
[SCRIPT, STAGE and FEATURE] and 104 weeks [FILM]),
patients entered an open-label extension, where they were treated
with OCR500 62+MTX (SCRIPT, STAGE and FILM) or
OCR400+MTX (FEATURE) at the discretion of the investigator.
At the time that FILM was terminated, all patients had completed
52 weeks of DBPC treatment and only a few had completed 104
weeks and entered the open-label extension. Therefore, analysis of
the DBPC period for FILM included only the Week 52 data. At
the time that FEATURE, SCRIPT and STAGE were terminated,
all patients had completed the double-blind 48-week period. Upon
withdrawal from treatment, all patients were required to continue
in safety follow-up (SFU) for at least 48 weeks from the first
infusion of their last course and until their CD19+ B-cell counts
either returned to baseline level or the lower limit of normal (80
cells/ml), whichever was lower.
Safety Assessments
In each trial, clinical adverse events (AEs) and serious AEs
(SAEs) were recorded, and the intensity of AEs was graded using
the National Cancer Institute Common Toxicity Criteria (version
3) and coded according to MedDRA (version 12.1). Malignancies
were identified using the wide standard MedDRA query
Malignant or Unspecified Tumors. Serious infectious events (SIEs)
also included those requiring intravenous antibiotics. IRRs and
symptoms were recorded on a specifically designed page of the
case report form.
Immunogenicity and Pharmacodynamics
The primary pharmacodynamic (PD) marker for OCR is the
presence of CD20+ B cells in the blood. Because the presence of
OCR in serum could confound assays of CD20+ cells, CD19 was
used to measure the levels of peripheral B cells following treatment
(limit of detection, 0.056109 cells/l in conventional flow cytom-
etry). In each trial, serum samples were collected at prespecified
time points for the determination of human anti-human antibodies
(HAHAs) and B-cell levels (CD19+ cells). A bridging format
enzyme-linked immunosorbent assay was used to determine
HAHA titers. All positive samples were further confirmed by
competitive binding to anti-IgM, followed by implementation of
an additional decision tree to confirm or reject true positivity.
Statistical Analysis
Safety and PD analyses were conducted on the safety
population, which included all patients in each trial who were
randomized, received any part of an infusion of study drug, and
underwent at least one assessment of safety. Evaluation of the
safety data for each study led to the conduct of a fixed-effects
meta-analysis of SIEs. The incidence rate difference in SIEs from
placebo (PBO)+MTX during the DBPC period, weighted by study
size was calculated for both dose groups using data from all four
studies (STAGE, SCRIPT, FEATURE and FILM). An explor-
atory, hypothesis-generating analysis of risk factors for SIEs was
performed on STAGE, SCRIPT and FILM DBPC pooled data
sets. The multivariate approach (COX regression models)
investigated treatment group as a risk factor, with baseline
covariates that included but were not limited to age, body mass
index, body surface area, weight, race, region, previous use of
biological and nonbiological DMARDs, MTX dose, corticosteroid
Ocrelizumab Safety in Rheumatoid Arthritis
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use, RA disease duration, presence of selected comorbid condi-
tions and study.
All available malignancy data from baseline to long-term SFU
(up to 5 years of follow-up) in the 4 trials were pooled.
Immunogenicity results included all data available for the DBPC
periods.
PD data were analyzed using Kaplan-Meier methodology and
included all data available after each patient completed at least 72
weeks of SFU after the last dose in each study.
In all analyses in which the FEATURE study was included,
patients who received OCR200 or OCR400+MTX were grouped
together in the OCR200+MTX group.
Results
Patient Population
The safety analysis population comprised 2759 patients (868
patients treated with PBO+MTX, 1064 with OCR200+MTX and
827 with OCR500+MTX; Figure 1). The majority of patients
were female and white and had a mean age ranging from
approximately 49 to 55 years (Table 2). Disease duration varied
because of the different patient populations. Patients in SCRIPT
had long-standing RA, with a duration of approximately 11 to 12
years; patients in FILM had a considerably shorter disease
duration of approximately 1.2 years. Corticosteroid (,10 mg/d)
use varied from 39% to 42% in FILM to 56% to 62% in SCRIPT.
In SCRIPT, leflunomide was received by 10.1%, 15.2% and
14.5% of the PBO+MTX, OCR200+MTX and OCR500+MTX
groups, respectively, with mean doses of 19.6, 18.3 and 17.4 mg/
d, respectively. All other patients in SCRIPT and all patients in the
other trials received concomitant MTX.
Overall Safety Profile
In all 4 trials, the incidence of all AEs during the DBPC periods
was comparable in the PBO+MTX–treated and OCR+MTX–
treated patients (Table 3). Grade 3 AEs were relatively infrequent,
occurring in approximately 5% to 10% of patients across the
treatment groups, with no clear differences between the PBO+
MTX and OCR+MTX groups. The incidence of grade 4 AEs was
0% to 2.5%. AEs leading to patient withdrawal were infrequent;
the most common in all 4 trials were IRRs and infections. Patients
who received OCR500+MTX in FILM had a higher incidence of
AEs leading to withdrawal than did patients who received PBO+
MTX (5.9% vs 1.0%). Although the incidence of SAEs varied
across the trials, there were no clear differences in general between
the PBO+MTX and OCR+MTX groups or between the different
dose groups (Table 3); the percentages of patients reporting $1
SAE were approximately 8% to 14% (OCR200+MTX) and 11%
to 14% (OCR500+MTX), compared with 8% to 12% (PBO+
MTX). The most common SAEs overall were infections and
infestations. In STAGE and FEATURE, the occurrence of SAEs
in other system organ classes was infrequent and comparable
across treatment groups. In SCRIPT, serious musculoskeletal and
connective tissue disorders were reported more frequently by
patients in the PBO+MTX group (4.3%) compared with the
OCR200+MTX (2.5%) and OCR500+MTX (2.5%) groups; this
difference was mainly driven by an increased reporting of
‘‘exacerbation of RA.’’ The occurrence of SAEs in other system
organ classes in SCRIPT was infrequent and comparable across
treatment groups. In FILM, SAEs classified as respiratory,
thoracic, and mediastinal disorders occurred more frequently with
OCR500+MTX (2.5%) than with OCR200+MTX (0.5%) and
PBO+MTX (0%); the most common SAE in this body system was
interstitial lung disease, which was reported in 3 patients in the
OCR500+MTX group. The occurrence of other body-system
SAEs was infrequent and comparable across treatment groups.
Infusion-Related Reactions
The most common AEs overall were IRRs. The incidence of
IRRs was approximately 2 to 3 times higher in the OCR+MTX
group relative to the PBO+MTX group (Table 3). The highest
incidence of IRRs occurred during and following the first infusion
of the first course; the second infusion was tolerated better, and
IRRs became less frequent with subsequent infusions. The most
common symptoms were pruritus, pyrexia, flushing, laryngeal/
throat irritation, headache, nausea, rash, chills/rigors, hyperten-
sion, urticaria and dizziness. IRRs were reported slightly more
frequently with OCR500+MTX than with OCR200+MTX in
both STAGE and SCRIPT but at a similar frequency with both
OCR+MTX doses in FILM. Only 2 patients in STAGE and 1
patient in FILM reported a serious IRR. The 2 serious IRRs that
occurred in STAGE were recorded for 1 patient in each of the 2
OCR+MTX groups. Both occurred during the first infusion of the
first course and resolved following symptomatic treatment. In
addition, 1 patient (OCR500+MTX) had an anaphylactoid
reaction that began 45 min after the start of the first infusion of
the first course. The reaction resolved without sequelae following
symptomatic treatment. One patient in the OCR500+MTX group
Table 1. Summary of 4 Phase III Studies of Ocrelizumab.
Trial Name Patients Treated, n RA Characteristics Treatment Groups+MTXa
Duration of PBO-Controlled
Period, weeks
STAGE 1006 MTX-IR; 51% to 54% steroid use; Baseline
DAS28 <6.4
PBO (n = 320); OCR200 (n = 343);
OCR500 (n = 343)
48
SCRIPT 836 TNF-IR; 56% to 62% steroid use; Baseline
DAS28 <6.5
PBO (n = 277); OCR200 (n = 277);
OCR500 (n = 282)
48
FEATURE 312 MTX-IR/biological DMARD-IR; 52% to 59%
steroid use; Baseline DAS28 <6.5
PBO (n = 64); OCR200 (n = 131);
OCR400 (n = 117)
24
FILM 605 MTX-naı̈ve; 39% to 42% steroid use;
Baseline DAS28 <7.0
PBO (n = 207); OCR200 (n = 196);
OCR500 (n = 202)
104b
Abbreviations: DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; IR, inadequate responder; MTX, methotrexate; OCR200,
ocrelizumab 200 mg62; OCR500, ocrelizumab 500 mg62; PBO, placebo; RA, rheumatoid arthritis; TNF, tumor necrosis factor.
aAll patients in all studies received background MTX 7.5 to 25 mg/week (7.5–20 mg/week in FILM), except for in SCRIPT, in which MTX or leflunomide was permitted.
Treatment with corticosteroids (#10 mg/day prednisolone or equivalent) was permitted in all studies provided the dose was stable 4 weeks prior to baseline.
bStudy terminated early. Safety evaluation conducted for 52-week data.
doi:10.1371/journal.pone.0087379.t001
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Figure 1. Patient disposition flow diagram of pooled safety population.
doi:10.1371/journal.pone.0087379.g001
Table 2. Baseline Patient Characteristics in Pooled Safety Populationsa.
Characteristic PBO+MTX
b OCR200+MTXb OCR500+MTXb
(n = 868) (n = 1064) (n = 827)
Female, % 74.0 to 87.5 77.3 to 82.5 80.0 to 83.7
White, % 68.8 to 74.4 65.9 to 73.0 67.0 to 75.6
Mean age, years 49.2 to 54.2 50.8 to 54.5 48.6 to 53.8
Mean RA disease duration, years 1.2 to 11.8 1.2 to 12.7 1.2 to 12.3
Serological status, %
— RF+/ACPA+ 83.0 to 87.9 80.2 to 87.8 77.1 to 86.1
— RF+/ACPA2 4.8 to 8.5 6.6 to 9.7 4.5 to 8.5
— RF–/ACPA+ 6.3 to 9.4 5.1 to 11.2 to 15.3
— RF–/ACPA2 0 to 1.6 0 to 1.2 0.7 to 1.5
SJC (66 joints), mean 16.6 to 21.1 16.5 to 19.4 17.1 to 19.5
TJC (68 joints), mean 26.0 to 31.6 26.2 to 30.8 26.4 to 30.0
CRP (mg/dl), mean 2.4 to 3.8 1.8 to 3.5 1.9 to 3.4
ESR (mm/h), mean 46.7 to 60.0 44.5 to 55.8 45.5 to 58.1
HAQ-DI, mean 1.5 to 1.8 1.5 to 1.8 1.5 to 1.7
DAS28-ESR, mean 6.4 to 7.0 6.4 to 7.0 6.4 to 6.9
Oral corticosteroid use, % 40 to 62 39 to 58 42 to 56
Abbreviations: ACPA, anti-citrullinated peptide antibody; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI,
Health Assessment Questionnaire Disease Index; MTX, methotrexate; OCR200, ocrelizumab 200 mg62; OCR500, ocrelizumab 500 mg62; PBO, placebo; RA, rheumatoid
arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.
aData shown as ranges (minimum and maximum values) across the 4 trials.
bAll patients in all studies received background MTX 7.5 to 25 mg/week (7.5 to 20 mg/week in FILM), except for in SCRIPT, in which MTX or leflunomide was permitted.
doi:10.1371/journal.pone.0087379.t002
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Table 3. Summary of Safety During the Double-Blind, Placebo-Controlled Periodsa.
Safety Profile PBO+MTXb OCR200+MTXb OCR500+MTXb
STAGE (MTX-IR)
Patients, n 320 343 343
Any AE, n (%) 254 (79.4) 282 (82.2) 287 (83.7)
— Grade 3, n (%) 25 (7.8) 20 (5.8) 25 (7.3)
— Grade 4, n (%) 2 (,1) 2 (,1) 2 (,1)
— Serious, n (%) 37 (11.6) 26 (7.6) 38 (11.1)
AEs leading to withdrawal, n (%) 5 (1.6) 5 (1.5) 6 (1.7)
Deaths, n (%) 1 (,1) 0 (0.0) 3 (,1)
IRRs, n (%) 31 (9.7) 69 (20.1) 80 (23.3)
— Serious, n (%) 0 (0.0) 1 (,1) 1 (,1)
Infections, n (%) 173 (54.1) 188 (54.8) 194 (56.6)
— Serious, n (%) 10 (3.1) 11 (3.2) 21 (6.1)
Malignancies, n (%) 6 (1.9) 3 (,1) 4 (1.2)
SCRIPT (TNF-IR)
Patients, n 277 277 282
Any AE, n (%) 227 (81.9) 232 (83.8) 238 (84.4)
— Grade 3, n (%) 28 (10.1) 25 (9.0) 28 (9.9)
— Grade 4, n (%) 1 (,1) 2 (,1) 3 (1.1)
— Serious, n (%) 32 (11.6) 40 (14.4) 32 (11.3)
AEs leading to withdrawal, n (%) 10 (3.6) 11 (4.0) 7 (2.5)
Deaths, n (%) 1 (,1) 0 (0.0) 0 (0.0)
IRRs, n (%) 30 (10.8) 53 (19.1) 67 (23.8)
— Serious, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Infections, n (%) 143 (51.6) 150 (54.2) 164 (58.2)
— Serious, n (%) 7 (2.5) 14 (5.1) 12 (4.3)
Malignancies, n (%) 5 (1.8) 7 (2.5) 2 (,1)
FEATURE (MTX-IR/biological DMARD-IR)
Patients, n 64 248 N/A
Any AE, n (%) 40 (62.5) 162 (65.3) —
— Grade 3, n (%) 4 (6.3) 8 (3.2) —
— Grade 4, n (%) 0 (0.0) 0 (0.0) —
— Serious, n (%) 5 (7.8) 5 (2.0) —
AEs leading to withdrawal, n (%) 2 (3.1) 3 (1.2) —
Deaths, n (%) 0 (0.0) 0 (0.0) —
IRRs, n (%) 7 (10.9) 53 (21.4) —
— Serious, n (%) 0 (0.0) 0 (0.0) —
Infections, n (%) 24 (37.5) 90 (36.3) —
— Serious, n (%) 2 (3.1) 5 (2.0) —
Malignancies, n (%) 0 (0.0) 1 (,1) —
FILM (MTX-naı̈ve)
Patients, n 207 196 202
Any AE, n (%) 167 (80.7) 171 (87.2) 167 (82.7)
— Grade 3, n (%) 16 (7.7) 18 (9.2) 24 (11.9)
— Grade 4, n (%) 0 (0.0) 1 (,1) 5 (2.5)
— Serious, n (%) 21 (10.1) 18 (9.2) 28 (13.9)
AEs leading to withdrawal, n (%) 2 (1.0) 3 (1.5) 12 (5.9)
Deaths, n (%) 2 (1.0) 2 (1.0) 1 (,1)
IRRs, n (%) 18 (8.7) 52 (26.5) 54 (26.7)
— Serious, n (%) 0 (0.0) 0 (0.0) 1 (,1)
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of FILM reported a serious IRR, which occurred approximately
12 hours after the second infusion of the second course. This
patient experienced weakness, headache, elevated blood pressure
and increased heart rate. Following hospitalization, the patient
received antihypertensive medication and the elevated blood
pressure resolved within 24 hours; the results of an electrocardio-
gram were normal.
Human Anti-Human Antibodies
At baseline, pre-infusion, 0.6% of all patients were HAHA-
positive—a result that was expected given the specificity and
sensitivity of the assay used. In all 4 trials, the proportion of
patients who developed HAHAs during the DBPC periods was
low and comparable between the OCR+MTX and PBO+MTX
groups. In FILM, the incidence of HAHAs over 52 weeks was 4/
202 (2.0%), 2/194 (1.0%), and 8/201 (4.0%) in the PBO+MTX,
OCR200+MTX and OCR500+MTX groups, respectively. The
corresponding HAHA incidences in SCRIPT over 48 weeks were
5/274 (1.8%), 8/273 (2.9%) and 7/277 (2.5%), respectively, and
in STAGE were 9/318 (2.8%), 16/338 (4.7%) and 7/339 (2.1%),
respectively. In FEATURE, the HAHA incidence ranged from
0% in patients who received PBO followed by OCR 200 mg62 to
10.7% (3/28) in patients who received PBO followed by OCR
400 mg61. Among all patients who were HAHA-positive post-
baseline, there was no apparent association between HAHA
positivity and corresponding CD19 counts or DAS28 scores in any
of the treatment groups across the 4 trials. Of the 3 patients who
experienced a serious IRR, none was HAHA-positive at any time
point tested; of the patients who were HAHA-positive, 4
experienced IRRs—all grade 1 or 2.
Serious Infections
In the DBPC periods of FILM, SCRIPT and STAGE, the rates
of SIEs (events per 100 patient-years) were higher in the
OCR500+MTX group than in the PBO+MTX group (Figure 2).
SIE rates were comparable between the OCR200+MTX and
PBO+MTX groups in these trials, with the exception of SCRIPT.
In SCRIPT, there was also a numerically higher rate of SIEs with
OCR200+MTX. The most common types of SIEs in all trials
were respiratory tract infections (most frequently pneumonia),
cellulitis and urinary tract infections.
A meta-analysis of SIEs was conducted. Following pooling of
data by treatment group, the weighted difference in incidence rate
per 100 patient-years from PBO in patients with SIEs was
significantly higher with OCR500+MTX (2.4; 95% CI, 0.3–4.5)
but not with OCR200+MTX (0.6; 95% CI, 21.3 to 2.4) (Figure 3,
A and B).
SIE rates by region for the individual studies (Asia versus Rest of
World) showed that SIE rates were particularly high in patients
recruited in Asia treated with OCR500+MTX (Figure 4). To
explore this further, individual patient data from the larger studies
was pooled (STAGE, SCRIPT and FILM) and an exploratory
COX regression analysis of risk factors for SIEs was performed.
After adjustment for all risk factors in the final model, the
following results were found: prior cardiac disease (hazard ratio
[HR], 2.29; 95% CI, 1.37–3.83; p = 0.002); use of oral cortico-
steroids at baseline (HR, 1.69; 95% CI, 1.08–2.65; p = 0.022);
history of diabetes (HR, 1.77; 95% CI, 1.02–3.05; p = 0.041);
treatment group (relative to PBO+MTX; OCR200+MTX [HR,
1.30; 95% CI, 0.76–2.24; p = 0.341] and OCR500+MTX [HR,
1.87; 95% CI, 1.13–3.11; p = 0.016]); and body weight (#47.5 kg
[5th percentile] relative to .47.5 kg; HR, 2.02; 95% CI, 1.00–
4.67; p = 0.049). In addition, after adjustment for these risk factors,
patients recruited in Asia appeared to have a higher risk of SIEs
compared with those recruited outside of Asia (HR [Asia vs non-
Asia] 1.78; 95% CI, 1.03–3.06; p = 0.039). It was not possible to
determine whether this effect was driven by race or region because
an overwhelming majority of Asian patients were recruited from
Figure 2. Rates of serious infectious events (SIEs) in the
double-blind, placebo-controlled periods. Multiple occurrences
of the same event in one individual were counted multiple times. MTX,
methotrexate; OCR200, ocrelizumab 200 mg62; OCR500, ocrelizumab
500 mg62; PBO, placebo; pt-yrs, patient-years.
doi:10.1371/journal.pone.0087379.g002
Table 3. Cont.
Safety Profile PBO+MTXb OCR200+MTXb OCR500+MTXb
Infections, n (%) 106 (51.2) 101 (51.5) 105 (52.0)
— Serious, n (%) 6 (2.9) 5 (2.6) 10 (5.0)
Malignancies, n (%) 2 (1.0) 0 (0.0) 1 (,1)
Abbreviations: AE, adverse event; DMARD, disease-modifying antirheumatic drug; IR, inadequate responder; IRR, infusion-related reaction; MTX, methotrexate; OCR200,
ocrelizumab 200 mg62; OCR500, ocrelizumab 500 mg62; PBO, placebo; TNF, tumor necrosis factor.
aMultiple events in individual patients were only counted once. Serious infections were defined as those requiring intravenous antibiotics and/or hospitalization or
classified as serious by the investigator. Any opportunistic infection was classified as a serious infection.
bAll patients in all studies received background MTX 7.5 to 25 mg/week (7.5 to 20 mg/week in FILM), except for in SCRIPT, in which MTX or leflunomide was permitted.
doi:10.1371/journal.pone.0087379.t003
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Figure 3. Fixed-effects meta-analysis of incidence rate differences in serious infectious events (SIEs). (A) OCR200+MTX; (B) OCR500+
MTX. The pooled rate difference accounts for study and is weighted according to the inverse of the estimated variance. These analyses are based on
patients with at least one event (does not count all events). Zero indicates no difference, and a positive value indicates that ocrelizumab (OCR) is
worse. MTX, methotrexate; OCR200, ocrelizumab 200 mg62; OCR500, ocrelizumab 500 mg62; PBO, placebo.
doi:10.1371/journal.pone.0087379.g003
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the Asian region. Study was not significant in the model after
adjustment for the risk factors specified. In the exploratory model
analyses, there were no statistically significant treatment interac-
tions, including a nonsignificant interaction between Asia and
treatment.
Data from the long-term SFU of patients during B-cell depletion
post-OCR treatment indicated that the incidence of SIEs
decreased over time, and the previously identified imbalance in
SIEs in the pivotal studies (STAGE and SCRIPT) in the
OCR500+MTX group disappeared. Rates of SIEs in Asian
countries also decreased over the long-term follow-up, although it
should be noted that the Asian groups consisted of small numbers
of patients, and the CIs were wide and overlapped with those of
the non-Asian population.
Opportunistic Infections
A total of 10 opportunistic infections were recorded during the
DBPC period. One occurred in the PBO+MTX group (Mycobac-
terium abscessus on the thigh in a patient from Thailand), 5 in the
OCR200+MTX group (de novo pulmonary tuberculosis [n = 2;
Mexico], hepatitis B reactivation [Japan], Mycobacterium kansasii
infection [Germany] and histoplasmosis [United States]) and 4 in
the OCR500+MTX group (Pneumocystis jiroveci [Japan], esophageal
candidiasis [France], Varicella pneumonia [South Korea] and
systemic Candida infection [South Korea]). No cases of progressive
multifocal leukoencephalopathy were recorded, and no fatal
outcomes resulted from opportunistic infection. The patient with
hepatitis B virus reactivation tested negative for hepatitis B surface
antigen, positive for hepatitis B core antibody and negative for
hepatitis B virus DNA at the time of enrollment. Approximately
300 patients with this serologic status for hepatitis B virus were
enrolled in the RA program, and no other cases of hepatitis B
reactivation were observed.
Malignancies
Pooled long-term follow-up data (of up to 5 years) from the four
studies showed that the rate of malignancies per 100 patient-years
was 1.18 (95% CI, 0.61–2.06) in the PBO+MTX group (n = 865;
1018 patient-years), 1.51 (95% CI, 0.99–2.19) in the OCR200+
MTX group (n = 1121; 1792 patient-years) and 1.41 (95% CI,
1.07–1.83) in the OCR 500+MTX group (n = 1849; 4034 patient-
years). The rate of all active treatments combined (n = 2434; 5826
Figure 4. Rates of serious infectious events (SIEs) by region. (A) STAGE; (B) SCRIPT; (C) FILM. MTX, methotrexate; OCR200, ocrelizumab
200 mg62; OCR500, ocrelizumab 500 mg62; PBO, placebo. ‘‘Asia’’ includes China, Hong Kong, Indonesia, Malaysia, Philippines, Republic of Korea,
Singapore, Taiwan, Thailand and Japan; ‘‘Other’’ includes North and South America, Europe and South Africa.
doi:10.1371/journal.pone.0087379.g004
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patient-years) was 1.44 (95% CI, 1.15–1.78). In summary, these
pooled analyses revealed no differences in the rate of malignancies
between treatment groups.
Deaths
Overall, 10 deaths occurred during the DBPC periods (Table 3).
The 4 deaths in the PBO+MTX groups were due to acute
myocardial infarction (n = 2), congestive cardiac failure (n = 1) and
rheumatoid vasculitis (n = 1). Of the 6 fatalities among OCR+
MTX-treated patients, 4 occurred in patients receiving the
OCR500 dose (1 each due to respiratory failure, sepsis, acute
myocardial infarction and ischemic stroke) and 2 in patients
receiving the OCR200 dose (1 each due to hemorrhagic stroke
and acute respiratory failure).
Pharmacodynamics
In all 4 trials, following the initiation of OCR treatment, a rapid
depletion of CD19+ B cells was observed in the OCR200+MTX
and OCR500+MTX groups as early as the first post-dose
evaluation time point at week 2, in contrast with the PBO+
MTX groups. Kaplan-Meier curves of times to B-cell repletion
(return of CD19+ levels to baseline or $80 cells/ml, whichever was
lower) in each of the 4 studies are shown in Figure 5. Data from
FILM allowed evaluation of the potential dose effect (after 2–4
courses) on B-cell repletion. No clinically meaningful difference
was observed in the median time to B-cell repletion from the first
dose of the last course between the OCR200+MTX (63.6 weeks;
95% CI, 53–72) and OCR500+MTX (66.1 weeks; 95% CI, 60–
73) groups. In addition, the median times to B-cell repletion were
similar between the OCR200+MTX and OCR500+MTX groups
in the DBPC period of FILM and between the OCR200/OL
OCR500+MTX and OCR500/OL OCR500+MTX groups in
the open-label extension of STAGE, respectively, suggesting that a
greater number of OCR re-treatments were not associated with a
longer repletion time. A slightly more prolonged B-cell repletion
profile was observed in SCRIPT when compared with the other
studies; this may be related to this patient population having more
severe, long-term disease with multiple previous treatments. There
was no indication that the time to B-cell repletion in patients
recruited in Asia was different from that in patients recruited
outside Asia.
Figure 5. Cumulative probability of B-cell repletion in each clinical trial. (A) STAGE; (B) SCRIPT; (C) FEATURE and (D) FILM. B-cell repletion
was defined as a return of CD19+ levels to baseline or 80 cells/mL, whichever was lower. Data summarized under the PBO/OL OCR500+MTX, OCR200/
OL OCR500+MTX and OCR500/OL OCR500+MTX treatment groups are OL data only. The x-axis represents the number of weeks since the first infusion
of the last course of OCR. MTX, methotrexate; OCR200, ocrelizumab 200 mg62; OCR500, ocrelizumab 500 mg62; OL, open-label; PBO, placebo.
doi:10.1371/journal.pone.0087379.g005
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Discussion
This report summarizes the safety results from the 4 phase III
trials conducted with OCR in patients with RA. The majority of
the population studied included patients with long-standing RA,
who had been using numerous immunosuppressive treatments in
the past and at least one immunosuppressive agent in combination
with OCR during participation in the studies. Approximately one-
third of the population studied previously received biological
DMARDs and more than one-half of the patients were
concomitantly receiving systemic corticosteroids. These factors
have to be taken into consideration when interpreting safety data
from the OCR clinical trial program in RA.
Although the overall safety profiles were generally comparable
between the PBO+MTX and both OCR+MTX dose groups, an
imbalance in the incidence of SIEs during the DBPC periods was
observed in the OCR500+MTX group. A meta-analysis of SIEs in
the DBPC treatment periods indicated a significantly higher rate
of SIEs among patients who were treated with OCR500+MTX
when compared with PBO+MTX. This was not observed with the
lower dose studied. Other factors associated with risk of SIEs were
prior cardiac disease, use of oral corticosteroids at baseline, and
history of diabetes. Patients recruited in Asia were also at a higher
risk of SIEs than were those recruited outside of Asia. Because
nearly all Asian patients were recruited in the Asian region, we
were unable to distinguish between geographic effects and
ethnicity. In addition, the low number of SIEs in the DBPC
period meant that we had limited statistical power in the analyses
of interactions of risk factors, such as Asian region with treatment.
Confounding factors may have contributed to the higher
incidence of opportunistic infections (9 cases across the OCR+
MTX groups: 5 cases in the OCR200+MTX group and 4 cases in
the OCR500+MTX group compared with a single case in the
PBO group) such as endemic areas for histoplasmosis in the
United States, tuberculosis in Mexico, and hepatitis B in Japan. In
addition, the patient with Candida infections was receiving high-
dose steroid treatment for concurrent medical conditions.
The clinical development of OCR was initiated in part with the
aim of evaluating the potential safety advantage of a humanized
molecule over chimeric antibodies. Humanization may be
expected to reduce the incidence of anti-drug antibody responses.
The incidence of HAHAs was low across the 4 trials (,5%) and, in
general, comparable between the pooled OCR+MTX and PBO+
MTX groups. There was no association between IRRs and
development of HAHAs. In addition, there were no clear
differences in the incidence of HAHAs when single-infusion and
dual-infusion OCR were compared, although, because the patient
numbers in FEATURE were small, the question of whether a
difference exists between single- and dual-infusion OCR remains
open. In a previous pooled analysis of approximately 2500 patients
in the rituximab RA clinical trial program, 11% of those treated
with rituximab developed human anti-chimeric antibodies [8].
As expected, both doses of OCR rapidly depleted B cells shortly
after infusion. The question was whether the higher rates of serious
infections seen in patients treated with OCR500+MTX could
have been explained, in part, by differences in B-cell depletion/
repletion profiles between the higher and lower doses. It should be
noted that evaluation of B-cell levels in clinical trials is limited by
measurement of peripheral CD19 counts only; however, the
analyses suggested that there was no difference in time to
peripheral B-cell repletion between the OCR500 and OCR200
doses. Moreover, the number of repeat treatment courses also did
not seem to have a clinically meaningful effect on time to B-cell
repletion.
The conclusion that the two doses of OCR, in combination with
MTX tested in the RA clinical trials did not demonstrate a
superior benefit-risk profile compared with available treatments
led to the termination of the clinical development program of
OCR in RA. OCR500+MTX demonstrated clinical benefit by
improving signs and symptoms of RA and radiographic outcomes
[10–13]; however this dose was associated with an increased
incidence of SIEs. OCR200+MTX did not show superior efficacy
compared with existing therapies, but was safe and well-tolerated.
The clinical development of OCR is continuing in multiple
sclerosis, for which there remains an unmet need for more effective
therapies and background immunosuppressant therapy is not
used. A phase II study in multiple sclerosis reported good efficacy
and safety data, with no imbalance in serious infections between
PBO and OCR (maximum dose up to 1000 mg62 for 24 weeks)
[14]. Phase III studies are continuing and, because of the low
prevalence of multiple sclerosis in Asia, no investigational sites in
that region have been included.
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